Business Context and Reporting Period
This Form 8-K was filed by Capricor Therapeutics, Inc. on May 9, 2014, reporting events occurring on May 5, 2014. The filing details the entry into a Material Definitive Agreement involving an Exclusive License Agreement with Cedars-Sinai Medical Center (CSMC).
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures for the reporting period. The document focuses on the terms of a new licensing agreement rather than periodic financial performance.
Material Changes and Agreement Terms
On May 5, 2014, Capricor, Inc. (a wholly-owned subsidiary of Capricor Therapeutics) entered into an Exclusive License Agreement with CSMC for intellectual property rights related to exosomes technology. Key terms include:
- License Scope: An exclusive, worldwide, royalty-bearing license with the right to sublicense for research, development, and commercialization.
- Future Rights: Capricor holds the exclusive right to negotiate for future rights arising from work by Dr. Eduardo Marbán; failure to agree results in a non-exclusive license subject to royalties.
- Financial Obligations: Capricor paid a license fee and reimbursed CSMC for patent prosecution costs. Future obligations include low single-digit royalties on sales and a single-digit percentage of sublicense consideration.
- Related Party Transactions: CSMC holds more than 10% of Capricor Therapeutics' outstanding capital stock. Dr. Eduardo Marbán, a CSMC Director, holds more than 10% of Capricor Therapeutics' stock and serves as Co-founder and Scientific Advisory Board Chairman.
Outlook, Risks, and Contingencies
The agreement includes specific termination clauses triggered by insolvency, bankruptcy, failure to meet development milestones, non-payment of royalties, or material breaches. The agreement continues until the last patent expires unless terminated earlier. Capricor intends to seek confidential treatment for certain terms of the agreement.
Investor Verification Checklist
- Verify the exact amount of the upfront license fee and reimbursement costs paid to CSMC, as specific figures are not disclosed in this summary.
- Confirm the specific "low single-digit" royalty percentages and the conditions for royalty reductions.
- Review the full text of the License Agreement (to be filed as an exhibit) for detailed development milestones and termination rights.
- Assess the impact of the related-party relationship between CSMC, Dr. Marbán, and Capricor Therapeutics on future governance and conflicts of interest.